Recursion Pharmaceuticals (RXRX)
(Delayed Data from NSDQ)
$5.53 USD
-0.27 (-4.66%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $5.49 -0.04 (-0.72%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RXRX 5.53 -0.27(-4.66%)
Will RXRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RXRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RXRX
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
RXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
Other News for RXRX
Decoding Recursion Pharmaceuticals Inc (RXRX): A Strategic SWOT Insight
Recursion Pharmaceuticals Q2 2025 Earnings: Revenue Surpasses Estimates at $19. ...
Recursion Sets $100 Million Partnership Goal by 202
Recursion Pharmaceuticals (RXRX) Exceeds Revenue Expectations in Q2
Recursion Pharmaceuticals (RXRX) Reports Mixed Q2 Results with Revenue Beat